Health ❯ Healthcare ❯ Medical Research

Cancer Treatment

Immunotherapy Pancreatic Cancer Breast Cancer Prostate Cancer Glioblastoma Colorectal Cancer Lung Cancer mRNA Vaccines Clinical Trials CAR T Cell Therapy

Moderna Merck Vaccine

Successful Phase 3 trial, personalized mRNA approach, and melanoma treatment advancements

Moderna and Merck Succeed in Phase 3 Trial of Personalized Melanoma mRNA Vaccine

The interim readout could change post‑surgery melanoma care pending full data review by regulators

Moderna and Merck Report Positive Phase 3 Results for Personalized mRNA Melanoma Vaccine

Stories older than 24h

DR5–Lig3 Feedback Loop Explains Why MSI Colorectal Tumors Respond to Immunotherapy

Selected Lung Transplants Linked to Higher One-Year Survival in Stage 4 Lung Cancer

Low-Frequency Ultrasound Selectively Kills Oral Cancer Cells

Experimental UCalgary CAR T Therapy GCAR1 Shrinks Rare Solid Tumours

CAR‑T Cells Targeting GPNMB Eradicate Glioblastoma in Preclinical Models

Fibroblasts Explain Why Lung Cancer Subtypes Respond Differently to Anti‑Angiogenic Drugs

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

U.S. Biotech Reports Major Survival Gain in Pancreatic Cancer as Hiroshima Plans 2028 Trial for MicroRNA Mesothelioma Drug

Daraxonrasib Nearly Doubles Median Survival in Previously Treated Metastatic Pancreatic Cancer

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

UC Study Links Some Antibody‑Drug Conjugates to High Rates of Severe Neutropenia

Experimental ERAP1 Inhibitor Plus Immunotherapy Shrinks Tumours in Early Trial

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Amivantamab Injection Eradicates Tumours in Treatment‑Resistant Head and Neck Cancer Trial

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

Gene Test Lets Many Over-40 Breast Cancer Patients Skip Chemotherapy

Mezigdomide Triplet Cuts Risk of Myeloma Progression by 52% in Phase 3 Trial